



## Research on Monoclonal Antibodies and Antibody Engineering

Collection Editor:

**Dr. Tatsuya Yamazaki**

Department of Microbiology and  
Immunology, School of Medicine,  
Aichi Medical University, Aichi  
480-1195, Japan

### Message from the Collection Editor

Dear Colleagues,

Our Special Issue, “Passive Immune Prophylaxis and Therapy”, focuses on passive immune prophylaxis and therapy using monoclonal antibodies (mAbs) for a variety of diseases. As you well know, current mAb-based products have attracted much attention for being one of the most effective molecular target drugs, and have also financially succeeded in developed markets. However, several obstacles hinder the widespread use of antibody drugs, such as a high production cost, the necessity of weekly or biweekly infusions due to short half-life (approximately 20 days), quality control, laborious development of the effective mAbs, shedding the target, antigenic variations and unwanted side effects.

To address the above problems, and to share your interesting knowledge in the field of passive immunization, we are inviting you to submit original research or review to this Special Issue on one of the following topics:

- (i) The methods of administration;
- (ii) Antibody engineering;
- (iii) How to develop the effective mAbs;
- (iv) Prophylactic or therapeutic mAb against virus.

We are looking forward to your interesting manuscript.

Dr. Tatsuya Yamazaki  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)